Le Pubblicazioni

Le principali pubblicazioni dei dottori della fondazione ARCO di Cuneo sono reperibili al sito http://www.ncbi.nlm.nih.gov/pubmed.

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Posted on 23 luglio 2015

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R. Int J Oncol. 2015 May 29. doi: 10.3892/ijo.2015.3026. Abstract O-6-methylguanine-DNA methyltransferase (MGMT) is an abundantly expressed nuclear protein dealkylating O6-methylguanine (O6-MG) DNA residue, thus correcting the mismatches of O6-MG with a thymine […]

The cisplatin-irradiation combination suggests that apoptosis is not a major determinant of clonogenic death.

Posted on 17 dicembre 2014

The cisplatin-irradiation combination suggests that apoptosis is not a major determinant of clonogenic death.

Lo Nigro C, Arnolfo E, Taricco E, Fruttero A, Russi EG, Lucio F, Ribero S, Comino A, Merlano M, Ungari S.

Anticancer Drugs. 2007 Jul;18(6):659-67.

 

Impact of erythropoietin on the effects of irradiation under hypoxia

Posted on 17 dicembre 2014

Impact of erythropoietin on the effects of irradiation under hypoxia

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.

 

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Posted on 17 dicembre 2014

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O’Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge […]

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.

Posted on 17 dicembre 2014

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, Vigo V, Bacigalupo A, Numico G, Crosetto N, Gasco M, Lo Nigro C, Vitiello R, Violante S, Garrone O. Ann Oncol. 2011 Mar;22(3):712-7. doi: 10.1093/annonc/mdq412. Epub 2010 […]

Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis.

Posted on 17 dicembre 2014

Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis.

Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, Lo Nigro C, Crook T, Machesky LM, Gusterson BA.

Am J Pathol. 2010 Nov;177(5):2323-33. doi: 10.2353/ajpath.2010.100209. Epub 2010 Sep 16.

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.

Posted on 17 dicembre 2014

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

Int J Oncol. 2010 Nov;37(5):1219-28.